Comparative Pharmacology
Head-to-head clinical analysis: LISINOPRIL versus PRINZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISINOPRIL versus PRINZIDE.
LISINOPRIL vs PRINZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased plasma angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, decreased sodium and water retention, and lower blood pressure.
PRINZIDE is a combination of lisinopril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Initial: 5-10 mg orally once daily. Maintenance: 10-40 mg orally once daily. Max: 80 mg/day.
Oral, 1-2 tablets daily; each tablet contains 25 mg hydrochlorothiazide and 5 mg lisinopril. Adjust based on blood pressure response; maximum daily dose: 2 tablets.
None Documented
None Documented
Clinical Note
moderateLisinopril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid."
Clinical Note
moderateLisinopril + Bumetanide
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide."
Clinical Note
moderateLisinopril + Benzydamine
"The risk or severity of adverse effects can be increased when Lisinopril is combined with Benzydamine."
Clinical Note
moderateLisinopril + Estrone sulfate
Terminal half-life approximately 12 hours (range 11–13 hours); clinical context: once-daily dosing for hypertension and heart failure; accumulation occurs with renal impairment.
Lisinopril: terminal half-life 12 hours (effective half-life 30 hours due to prolonged ACE binding). Hydrochlorothiazide: terminal half-life 6-15 hours (biphasic, initial phase 2-4 h, terminal phase 6-15 h) with prolonged terminal phase in renal impairment.
Renal: 100% unchanged via glomerular filtration and tubular secretion; negligible biliary/fecal elimination.
Lisinopril is excreted unchanged in urine (100% renal elimination); hydrochlorothiazide is excreted 95% renally as unchanged drug and 5% via bile.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor / Diuretic Combination
"The serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril."